Dr. Pandya loves teaching introductory health decision science and conducting research built on these methods. His areas of interest are: 1) applied decision science studies evaluating cardiovascular disease policies; 2) connecting cost-effectiveness analysis with broader value-based health policies being implemented or piloted in U.S. health reform; and 3) methodological topics within disease simulation modeling (calibration, validation, value of information). His research has been covered in The New York Times, National Public Radio, NBC Nightly News, and other media outlets.
Before joining HPM, Dr. Pandya served as Assistant Professor of Healthcare Policy and Research with a secondary appointment in the Department of Radiology at Weill Cornell Medical College from 2012-2014. He graduated from the Harvard PhD Program in Health Policy in 2012, and holds an MPH from Yale University in Health Policy and Administration and a BS from Cornell University in Nutritional Sciences. Prior to entering the PhD program, he worked for two years at a health economics/outcomes research consulting firm.
He received the “Outstanding Paper by a Young Investigator Award” from the Society for Medical Decision Making (SMDM) in 2016. He was one of three recipients of the “Teaching Citation Award” from the Harvard T.H. Chan School of Public Health in 2017. He received a “Centre for Health Economics Research Fellowship Award” from the University of York in 2018 (visitation in 2019). He was elected as an SMDM trustee in 2019. He received the “Roger L. Nichols Excellence in Teaching Award” from the Harvard T.H. Chan School of Public Health in 2022. Dr. Pandya has received grant funding as principal investigator from the National Institutes of Health (R01NS104143, 2018-2023) and the American Heart Association (14CRP18730014, 2014-2015).
PhD, 2012, Harvard University
MPH, 2005, Yale University
BS, 2003, Cornell University
Decision Analysis for Health and Medical Practices (RDS 280, Fall-2)
Persad G, Pandya A. A Comprehensive COVID-19 Response: The Need for Economic Evaluation. N Engl J Med. 2022 May 4.
Pandya A, Paulden M, Zhu J, Lavelle T, Hammitt J. Trends in Author-Reported Cost-Effectiveness Thresholds in the US from 1995-2018: Implications for Discount Rates. Med Decis Making. 2022 May 7:272989X221097106.
Bilinski A, MacKay E, Salomon JA, Pandya A. Costly Disagreements: A Survey of Researchers on Cost-Effectiveness and Affordability. Value Health. 2022 Feb 23:S1098-3015(22)00007-9.
Pandya A, Griffin S, Walker S. Responding to health-improving but cost-ineffective care. JAMA Health Forum. March 2021.
Pandya A, Soeteman DI, Gupta A, Kamel H, Mushlin AI, Rosenthal MB. Can Pay-for Performance Incentive Levels be Determined using a Cost-Effectiveness Framework? Circ Cardiovasc Qual Outcomes. 2020 Jul 3: CIRCOUTCOMES120006492
Spahillari A, Zhu J, Hunink MMG, Ferket BS, Carr JJ, Terry JG, Nelson C, Mwasongwe S, Mentz RJ, O’Brien EC, Correa A, Shah RV, Murthy VL, Pandya A. Cost-Effectiveness of Contemporary Guidelines with or without Coronary Artery Calcium for Atherosclerotic Cardiovascular Disease Prevention in African Americans. JAMA Cardiol. 2020 May 13:e201240.
Choi SE, Sima C, Pandya A. Impact of Treating Oral Disease on Preventing Vascular Diseases: A Model-Based Cost-Effectiveness Analysis of Periodontal Treatment among Patients with Type 2 Diabetes. Diabetes Care. 2019 Dec 27. pii: dc191201.
Pandya A, Asch DA, Volpp KG, Sy S, Zhu J, Toxel AB, Weinstein MC, Rosenthal MB, Gaziano TA. Cost-effectiveness of Financial Incentives on Lipid Levels.
Pandya A, Doran T, Zhu J, Walker S, Arntson E, Ryan A. Modeling the Cost-Effectiveness of Pay-for-Performance in Primary Care for the UK. BMC Med. 2018 Aug 29;16(1):135.
Pandya A. Adding Cost-effectiveness to Define Low-Value Care. JAMA. 2018 May 15;319(19):1977-1978.
Pandya A, Sy S, Cho S, Alam S, Weinstein MC, Gaziano TA. Validation of a Cardiovascular Disease Policy Micro-Simulation Model using Both Survival and Receiver Operating Characteristics Curves. Med Decis Making. 2017 Oct;37(7):802-814.
Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA. 2015 Jul 14;314(2):142-50.
Pandya A, Gupta A, Kamel H, Navi B, Sanelli PC, Schackman BR. Cost-effectiveness of cerebrovascular reserve assessment to guide management of patients with asymptomatic carotid stenosis. Radiology. 2015 Feb;274(2):455-63.
Pandya A, Weinstein MC, Cutler D, Salomon JA, Gaziano TA. Who needs laboratories and who needs statins? Comparative and cost effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines. Circ Cardiovasc Qual Outcomes. 2014 Jan; 7(1):25-32.
Pandya A, Gaziano TA, Weinstein MC, Cutler D. More Americans Living Longer With Cardiovascular Disease Will Increase Costs While Lowering Quality Of Life. Health Aff (Millwood). 2013 Oct;32(10):1706-1714.